Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	peptide lactyltransferase (CoA-dependent) activity	CREBBP EP300	4.53e-06	2	43	2	GO:0120300
GeneOntologyMolecularFunction	histone H3K27 acetyltransferase activity	CREBBP EP300	4.53e-06	2	43	2	GO:0044017
GeneOntologyMolecularFunction	histone H3K18 acetyltransferase activity	CREBBP EP300	1.36e-05	3	43	2	GO:0043993
GeneOntologyMolecularFunction	glycogen phosphorylase activity	PYGB PYGM	1.36e-05	3	43	2	GO:0008184
GeneOntologyMolecularFunction	1,4-alpha-oligoglucan phosphorylase activity	PYGB PYGM	4.51e-05	5	43	2	GO:0004645
GeneOntologyMolecularFunction	histone acetyltransferase activity	NAA60 CREBBP EP300	1.80e-04	51	43	3	GO:0004402
GeneOntologyMolecularFunction	peptide-lysine-N-acetyltransferase activity	NAA60 CREBBP EP300	2.26e-04	55	43	3	GO:0061733
GeneOntologyMolecularFunction	pyridoxal phosphate binding	PYGB PYGM ALB	2.38e-04	56	43	3	GO:0030170
GeneOntologyMolecularFunction	vitamin B6 binding	PYGB PYGM ALB	2.51e-04	57	43	3	GO:0070279
GeneOntologyMolecularFunction	peptide N-acetyltransferase activity	NAA60 CREBBP EP300	2.92e-04	60	43	3	GO:0034212
GeneOntologyMolecularFunction	histone H3 acetyltransferase activity	CREBBP EP300	4.67e-04	15	43	2	GO:0010484
GeneOntologyMolecularFunction	Arp2/3 complex binding	GMFB GMFG	5.33e-04	16	43	2	GO:0071933
GeneOntologyMolecularFunction	N-acetyltransferase activity	NAA60 CREBBP EP300	6.32e-04	78	43	3	GO:0008080
GeneOntologyMolecularFunction	polypeptide N-acetylgalactosaminyltransferase activity	GALNT14 GALNT10	8.40e-04	20	43	2	GO:0004653
GeneOntologyMolecularFunction	SMAD binding	FOXA2 CREBBP EP300	8.41e-04	86	43	3	GO:0046332
GeneOntologyMolecularFunction	peroxisome proliferator activated receptor binding	CREBBP EP300	9.27e-04	21	43	2	GO:0042975
GeneOntologyMolecularFunction	hexosyltransferase activity	GALNT14 PYGB PYGM GALNT10	1.08e-03	211	43	4	GO:0016758
GeneOntologyMolecularFunction	histone H4 acetyltransferase activity	NAA60 EP300	1.11e-03	23	43	2	GO:0010485
GeneOntologyMolecularFunction	N-acyltransferase activity	NAA60 CREBBP EP300	1.38e-03	102	43	3	GO:0016410
GeneOntologyMolecularFunction	acetyltransferase activity	NAA60 CREBBP EP300	1.46e-03	104	43	3	GO:0016407
GeneOntologyMolecularFunction	acetylgalactosaminyltransferase activity	GALNT14 GALNT10	2.58e-03	35	43	2	GO:0008376
GeneOntologyMolecularFunction	oxygen binding	ALB SOD2	2.88e-03	37	43	2	GO:0019825
GeneOntologyMolecularFunction	bHLH transcription factor binding	CREBBP EP300	2.88e-03	37	43	2	GO:0043425
GeneOntologyMolecularFunction	glycosyltransferase activity	GALNT14 PYGB PYGM GALNT10	3.36e-03	288	43	4	GO:0016757
GeneOntologyMolecularFunction	phosphotransferase activity, phosphate group as acceptor	TJP2 IP6K1	3.52e-03	41	43	2	GO:0016776
GeneOntologyMolecularFunction	carbohydrate binding	GALNT14 PYGB PYGM GALNT10	4.37e-03	310	43	4	GO:0030246
GeneOntologyMolecularFunction	vitamin binding	PYGB PYGM ALB	5.01e-03	161	43	3	GO:0019842
GeneOntologyMolecularFunction	transcription coactivator binding	CREBBP EP300	6.04e-03	54	43	2	GO:0001223
GeneOntologyMolecularFunction	inorganic cation transmembrane transporter activity	TRPM6 TMEM63B CNNM4 ATP1B4 NDUFB10	1.08e-02	627	43	5	GO:0022890
GeneOntologyMolecularFunction	p53 binding	CREBBP EP300	1.20e-02	77	43	2	GO:0002039
GeneOntologyMolecularFunction	histone modifying activity	NAA60 CREBBP EP300	1.31e-02	229	43	3	GO:0140993
GeneOntologyMolecularFunction	protein kinase inhibitor activity	GMFB GMFG	1.32e-02	81	43	2	GO:0004860
GeneOntologyBiologicalProcess	actin filament debranching	GMFB GMFG	4.45e-06	2	44	2	GO:0071846
GeneOntologyBiologicalProcess	N-terminal protein amino acid acetylation	NAA60 CREBBP EP300	4.97e-06	16	44	3	GO:0006474
GeneOntologyBiologicalProcess	N-terminal peptidyl-lysine acetylation	CREBBP EP300	2.66e-05	4	44	2	GO:0018076
GeneOntologyBiologicalProcess	N-terminal protein amino acid modification	NAA60 CREBBP EP300	3.18e-05	29	44	3	GO:0031365
GeneOntologyBiologicalProcess	negative regulation of Arp2/3 complex-mediated actin nucleation	GMFB GMFG	9.28e-05	7	44	2	GO:0034316
GeneOntologyBiologicalProcess	presynaptic membrane assembly	IL1RAPL1 PTEN	1.98e-04	10	44	2	GO:0097105
GeneOntologyBiologicalProcess	negative regulation of actin nucleation	GMFB GMFG	1.98e-04	10	44	2	GO:0051126
HumanPheno	Plantar crease between first and second toes	CREBBP EP300	1.05e-05	2	17	2	HP:0008107
HumanPheno	Aortic isthmus hypoplasia	CREBBP EP300	1.05e-05	2	17	2	HP:0034227
HumanPheno	High axial triradius	CREBBP EP300	1.05e-05	2	17	2	HP:0001042
HumanPheno	Skin appendage neoplasm	PTEN CREBBP EP300	2.44e-05	18	17	3	HP:0012842
HumanPheno	Laryngeal cartilage malformation	CREBBP EP300	3.14e-05	3	17	2	HP:0008752
HumanPheno	Phobia	CREBBP EP300	3.14e-05	3	17	2	HP:5200232
HumanPheno	Agoraphobia	CREBBP EP300	3.14e-05	3	17	2	HP:0000756
HumanPheno	Humoral immunodeficiency	CREBBP EP300	3.14e-05	3	17	2	HP:0005363
HumanPheno	Prominent nasal septum	CREBBP EP300	3.14e-05	3	17	2	HP:0005322
HumanPheno	Radial deviation of thumb terminal phalanx	CREBBP EP300	3.14e-05	3	17	2	HP:0005895
HumanPheno	Agenesis of permanent teeth	C1R CREBBP EP300	5.25e-05	23	17	3	HP:0006349
HumanPheno	Trichiasis	CREBBP EP300	6.27e-05	4	17	2	HP:0001128
HumanPheno	Visceral hemangioma	CREBBP EP300	6.27e-05	4	17	2	HP:0410266
HumanPheno	Talon cusp	CREBBP EP300	6.27e-05	4	17	2	HP:0011087
HumanPheno	Widened distal phalanges	CREBBP EP300	6.27e-05	4	17	2	HP:0006200
HumanPheno	Vascular ring	CREBBP EP300	6.27e-05	4	17	2	HP:0010775
HumanPheno	Hepatic hemangioma	CREBBP EP300	6.27e-05	4	17	2	HP:0031207
HumanPheno	Papillary cystadenoma of the epididymis	CREBBP EP300	1.04e-04	5	17	2	HP:0009715
HumanPheno	Supernumerary cusp	CREBBP EP300	1.04e-04	5	17	2	HP:0033777
HumanPheno	Epididymal neoplasm	CREBBP EP300	1.04e-04	5	17	2	HP:0030421
HumanPheno	Large foramen magnum	CREBBP EP300	1.56e-04	6	17	2	HP:0002700
HumanPheno	Abnormal branching pattern of the aortic arch	MMP21 CREBBP EP300	1.58e-04	33	17	3	HP:0011587
HumanPheno	Abnormality of the plantar skin of foot	C1R PTEN ANAPC1 CREBBP EP300	1.79e-04	171	17	5	HP:0100872
HumanPheno	Abnormal number of permanent teeth	C1R CREBBP EP300	1.89e-04	35	17	3	HP:0011044
HumanPheno	Carious teeth	CNNM4 PTEN ANAPC1 CREBBP EP300	1.95e-04	174	17	5	HP:0000670
HumanPheno	Hydrocele testis	PTEN CREBBP EP300	2.06e-04	36	17	3	HP:0000034
HumanPheno	Deviated nasal septum	CREBBP EP300	2.18e-04	7	17	2	HP:0004411
HumanPheno	Capillary hemangioma	PTEN CREBBP EP300	2.62e-04	39	17	3	HP:0005306
HumanPheno	Cellular immunodeficiency	PTEN CREBBP EP300	2.62e-04	39	17	3	HP:0005374
HumanPheno	Pilomatrixoma	CREBBP EP300	3.72e-04	9	17	2	HP:0030434
HumanPheno	Cervical cord compression	CREBBP EP300	3.72e-04	9	17	2	HP:0002341
HumanPheno	Meningioma	PTEN CREBBP EP300	3.76e-04	44	17	3	HP:0002858
HumanPheno	Hypermelanotic macule	C1R PTEN ANAPC1 CREBBP EP300	3.82e-04	201	17	5	HP:0001034
HumanPheno	Broad phalanx of the toes	PTEN CREBBP EP300	4.57e-04	47	17	3	HP:0010174
HumanPheno	Frontal hirsutism	CREBBP EP300	4.64e-04	10	17	2	HP:0011335
HumanPheno	Pulmonary artery hypoplasia	MMP21 MGP	4.64e-04	10	17	2	HP:0004971
HumanPheno	Abnormal subclavian artery morphology	CREBBP EP300	5.67e-04	11	17	2	HP:0031251
HumanPheno	Abnormal dental enamel morphology	CNNM4 PTEN ANAPC1 CREBBP EP300	5.92e-04	221	17	5	HP:0000682
HumanPheno	Macule	C1R PTEN ANAPC1 CREBBP EP300	7.70e-04	234	17	5	HP:0012733
HumanPheno	Facial grimacing	CREBBP EP300	8.00e-04	13	17	2	HP:0000273
HumanPheno	Keloids	CREBBP EP300	8.00e-04	13	17	2	HP:0010562
HumanPheno	Abnormality of the radial head	ANAPC1 CREBBP EP300	8.08e-04	57	17	3	HP:0003995
HumanPheno	Irregular hyperpigmentation	C1R PTEN ANAPC1 CREBBP EP300	8.32e-04	238	17	5	HP:0007400
HumanPheno	Abnormal odontoid tissue morphology	CNNM4 PTEN ANAPC1 CREBBP EP300	8.32e-04	238	17	5	HP:3000050
HumanPheno	Cafe-au-lait spot	PTEN ANAPC1 CREBBP EP300	9.07e-04	137	17	4	HP:0000957
HumanPheno	Duplication of phalanx of hallux	CREBBP EP300	9.32e-04	14	17	2	HP:0010066
HumanPheno	Hypoplastic aortic arch	CREBBP EP300	9.32e-04	14	17	2	HP:0012304
HumanPheno	Parietal foramina	CREBBP EP300	9.32e-04	14	17	2	HP:0002697
HumanPheno	Duplication of phalanx of toe	CREBBP EP300	1.07e-03	15	17	2	HP:0010181
HumanPheno	Social and occupational deterioration	CREBBP EP300	1.07e-03	15	17	2	HP:0007086
HumanPheno	Square face	CREBBP EP300	1.22e-03	16	17	2	HP:0000321
HumanPheno	macules	C1R PTEN ANAPC1 CREBBP EP300	1.29e-03	262	17	5	HP:0200031
HumanPheno	Premature thelarche	CREBBP EP300	1.38e-03	17	17	2	HP:0010314
Domain	-	CREBBP EP300	5.18e-06	2	43	2	1.10.246.20
Domain	zf-TAZ	CREBBP EP300	5.18e-06	2	43	2	PF02135
Domain	ZF_TAZ	CREBBP EP300	5.18e-06	2	43	2	PS50134
Domain	Nuc_rcpt_coact_CREBbp	CREBBP EP300	5.18e-06	2	43	2	IPR014744
Domain	HAT_KAT11	CREBBP EP300	5.18e-06	2	43	2	PF08214
Domain	KIX	CREBBP EP300	5.18e-06	2	43	2	PS50952
Domain	ZnF_TAZ	CREBBP EP300	5.18e-06	2	43	2	SM00551
Domain	CBP_P300_HAT	CREBBP EP300	5.18e-06	2	43	2	IPR031162
Domain	Histone_AcTrfase_Rtt109/CBP	CREBBP EP300	5.18e-06	2	43	2	IPR013178
Domain	DUF902	CREBBP EP300	5.18e-06	2	43	2	PF06001
Domain	-	CREBBP EP300	5.18e-06	2	43	2	1.20.1020.10
Domain	RING_CBP-p300	CREBBP EP300	5.18e-06	2	43	2	IPR010303
Domain	KAT11	CREBBP EP300	5.18e-06	2	43	2	SM01250
Domain	-	CREBBP EP300	5.18e-06	2	43	2	1.10.1630.10
Domain	Znf_TAZ	CREBBP EP300	5.18e-06	2	43	2	IPR000197
Domain	KIX_dom	CREBBP EP300	5.18e-06	2	43	2	IPR003101
Domain	Creb_binding	CREBBP EP300	5.18e-06	2	43	2	PF09030
Domain	KIX	CREBBP EP300	5.18e-06	2	43	2	PF02172
Domain	GMF	GMFB GMFG	5.18e-06	2	43	2	IPR011171
Domain	CBP_P300_HAT	CREBBP EP300	5.18e-06	2	43	2	PS51727
Domain	Glyco_trans_35	PYGB PYGM	1.55e-05	3	43	2	IPR000811
Domain	PHOSPHORYLASE	PYGB PYGM	1.55e-05	3	43	2	PS00102
Domain	SAM_MT_NNMT_PNMT_TEMT	NNMT INMT	1.55e-05	3	43	2	PS51681
Domain	NNMT_PNMT_TEMT	NNMT INMT	1.55e-05	3	43	2	PF01234
Domain	NNMT/PNMT/TEMT_CS	NNMT INMT	1.55e-05	3	43	2	IPR025820
Domain	NNMT_PNMT_TEMT	NNMT INMT	1.55e-05	3	43	2	PS01100
Domain	Phosphorylase	PYGB PYGM	1.55e-05	3	43	2	PF00343
Domain	Glycg_phsphrylas	PYGB PYGM	1.55e-05	3	43	2	IPR011833
Domain	NNMT_TEMT_trans	NNMT INMT	1.55e-05	3	43	2	IPR000940
Domain	Nuc_rcpt_coact	CREBBP EP300	7.72e-05	6	43	2	IPR009110
Domain	ADF	GMFB GMFG	2.30e-04	10	43	2	SM00102
Domain	Cofilin_ADF	GMFB GMFG	2.30e-04	10	43	2	PF00241
Domain	ADF-H	GMFB GMFG	2.30e-04	10	43	2	IPR002108
Domain	ADF_H	GMFB GMFG	2.30e-04	10	43	2	PS51263
Domain	ZF_ZZ_2	CREBBP EP300	7.74e-04	18	43	2	PS50135
Domain	ZF_ZZ_1	CREBBP EP300	7.74e-04	18	43	2	PS01357
Domain	ZZ	CREBBP EP300	7.74e-04	18	43	2	PF00569
Domain	Znf_ZZ	CREBBP EP300	8.64e-04	19	43	2	IPR000433
Domain	ZnF_ZZ	CREBBP EP300	8.64e-04	19	43	2	SM00291
Domain	-	GMFB GMFG	1.38e-03	24	43	2	3.40.20.10
Domain	ADF-H/Gelsolin-like_dom	GMFB GMFG	1.38e-03	24	43	2	IPR029006
Domain	Ricin_B_lectin	GALNT14 GALNT10	1.50e-03	25	43	2	PF00652
Domain	Bromodomain_CS	CREBBP EP300	1.62e-03	26	43	2	IPR018359
Domain	RICIN	GALNT14 GALNT10	1.88e-03	28	43	2	SM00458
Domain	RICIN_B_LECTIN	GALNT14 GALNT10	1.88e-03	28	43	2	PS50231
Domain	Glyco_trans_2-like	GALNT14 GALNT10	2.16e-03	30	43	2	IPR001173
Domain	Ricin_B_lectin	GALNT14 GALNT10	2.16e-03	30	43	2	IPR000772
Domain	Glycos_transf_2	GALNT14 GALNT10	2.16e-03	30	43	2	PF00535
Domain	BROMODOMAIN_1	CREBBP EP300	3.28e-03	37	43	2	PS00633
Domain	Bromodomain	CREBBP EP300	3.45e-03	38	43	2	PF00439
Domain	BROMODOMAIN_2	CREBBP EP300	4.01e-03	41	43	2	PS50014
Domain	BROMO	CREBBP EP300	4.20e-03	42	43	2	SM00297
Domain	Bromodomain	CREBBP EP300	4.20e-03	42	43	2	IPR001487
Domain	-	CREBBP EP300	4.20e-03	42	43	2	1.20.920.10
Pathway	WP_HEMATOPOIETIC_STEM_CELL_GENE_REGULATION_BY_GABP_ALPHABETA_COMPLEX	PTEN CREBBP EP300	1.37e-05	21	32	3	M39593
Pathway	BIOCARTA_PELP1_PATHWAY	CREBBP EP300	4.97e-05	5	32	2	MM1575
Pathway	REACTOME_NFE2L2_REGULATING_INFLAMMATION_ASSOCIATED_GENES	CREBBP EP300	4.97e-05	5	32	2	M48020
Pathway	REACTOME_NFE2L2_REGULATING_ER_STRESS_ASSOCIATED_GENES	CREBBP EP300	4.97e-05	5	32	2	M48023
Pathway	REACTOME_LRR_FLII_INTERACTING_PROTEIN_1_LRRFIP1_ACTIVATES_TYPE_I_IFN_PRODUCTION	CREBBP EP300	4.97e-05	5	32	2	M27228
Pathway	BIOCARTA_PELP1_PATHWAY	CREBBP EP300	7.45e-05	6	32	2	M22062
Pathway	BIOCARTA_PPARG_PATHWAY	CREBBP EP300	1.04e-04	7	32	2	MM1573
Pathway	REACTOME_REGULATION_OF_BETA_CELL_DEVELOPMENT	FOXA2 CREBBP EP300	1.15e-04	42	32	3	M17541
Pathway	PID_HNF3A_PATHWAY	FOXA2 CREBBP EP300	1.32e-04	44	32	3	M285
Pathway	BIOCARTA_PPARG_PATHWAY	CREBBP EP300	1.39e-04	8	32	2	M22058
Pathway	REACTOME_NFE2L2_REGULATING_MDR_ASSOCIATED_ENZYMES	CREBBP EP300	1.39e-04	8	32	2	M48022
Pathway	REACTOME_REGULATION_OF_NFE2L2_GENE_EXPRESSION	CREBBP EP300	1.39e-04	8	32	2	M48024
Pathway	REACTOME_NFE2L2_REGULATES_PENTOSE_PHOSPHATE_PATHWAY_GENES	CREBBP EP300	1.39e-04	8	32	2	M46443
Pathway	KEGG_CELL_CYCLE	ANAPC1 CREBBP EP300 CDC23	1.75e-04	125	32	4	M7963
Pathway	KEGG_MEDICUS_REFERENCE_GLYCOGEN_DEGRADATION	PYGB PYGM	1.78e-04	9	32	2	M47621
Pathway	WP_METHYLATION_PATHWAYS	NNMT INMT	1.78e-04	9	32	2	M39493
Pathway	KEGG_MEDICUS_REFERENCE_TLR3_IRF3_SIGNALING_PATHWAY	CREBBP EP300	1.78e-04	9	32	2	M47451
Pathway	WP_METHYLATION	NNMT INMT	1.78e-04	9	32	2	MM15836
Pathway	PID_FOXO_PATHWAY	CREBBP EP300 SOD2	1.82e-04	49	32	3	M136
Pathway	REACTOME_REGULATION_OF_FOXO_TRANSCRIPTIONAL_ACTIVITY_BY_ACETYLATION	CREBBP EP300	2.22e-04	10	32	2	M27945
Pathway	BIOCARTA_CARM1_PATHWAY	CREBBP EP300	2.71e-04	11	32	2	MM1521
Pathway	REACTOME_NFE2L2_REGULATING_TUMORIGENIC_GENES	CREBBP EP300	2.71e-04	11	32	2	M48021
Pathway	REACTOME_REGULATION_OF_GENE_EXPRESSION_BY_HYPOXIA_INDUCIBLE_FACTOR	CREBBP EP300	2.71e-04	11	32	2	M26924
Pathway	BIOCARTA_CARM1_PATHWAY	CREBBP EP300	3.25e-04	12	32	2	M7968
Pathway	REACTOME_ACTIVATION_OF_THE_TFAP2_AP_2_FAMILY_OF_TRANSCRIPTION_FACTORS	CREBBP EP300	3.25e-04	12	32	2	M27765
Pathway	WP_PATHWAYS_AFFECTED_IN_ADENOID_CYSTIC_CARCINOMA	PTEN CREBBP EP300	4.22e-04	65	32	3	M39682
Pathway	REACTOME_FOXO_MEDIATED_TRANSCRIPTION	CREBBP EP300 SOD2	4.41e-04	66	32	3	M27938
Pathway	REACTOME_GLYCOGEN_BREAKDOWN_GLYCOGENOLYSIS	PYGB PYGM	4.47e-04	14	32	2	M19193
Pathway	REACTOME_RUNX3_REGULATES_NOTCH_SIGNALING	CREBBP EP300	4.47e-04	14	32	2	M27808
Pathway	WP_UROTENSINIIMEDIATED_SIGNALING	PTEN CREBBP EP300	5.03e-04	69	32	3	M48052
Pathway	BIOCARTA_RELA_PATHWAY	CREBBP EP300	5.15e-04	15	32	2	MM1339
Pathway	BIOCARTA_RELA_PATHWAY	CREBBP EP300	5.15e-04	15	32	2	M10183
Pathway	BIOCARTA_PITX2_PATHWAY	CREBBP EP300	5.15e-04	15	32	2	MM1439
Pathway	REACTOME_TRAF3_DEPENDENT_IRF_ACTIVATION_PATHWAY	CREBBP EP300	5.15e-04	15	32	2	M953
Pathway	REACTOME_REGULATION_OF_GENE_EXPRESSION_IN_LATE_STAGE_BRANCHING_MORPHOGENESIS_PANCREATIC_BUD_PRECURSOR_CELLS	CREBBP EP300	5.87e-04	16	32	2	M27121
Pathway	KEGG_MEDICUS_REFERENCE_COHESIN_DISSOCIATION_IN_ANAPHASE	ANAPC1 CDC23	5.87e-04	16	32	2	M47871
Pathway	BIOCARTA_IL7_PATHWAY	CREBBP EP300	5.87e-04	16	32	2	M1296
Pathway	BIOCARTA_IL7_PATHWAY	CREBBP EP300	5.87e-04	16	32	2	MM1420
Pathway	KEGG_MEDICUS_PATHOGEN_HTLV_1_TAX_TO_SPINDLE_ASSEMBLY_CHECKPOINT_SIGNALING	ANAPC1 CDC23	5.87e-04	16	32	2	M47476
Pathway	BIOCARTA_PITX2_PATHWAY	CREBBP EP300	5.87e-04	16	32	2	M8516
Pathway	REACTOME_FOXO_MEDIATED_TRANSCRIPTION_OF_CELL_DEATH_GENES	CREBBP EP300	5.87e-04	16	32	2	M27940
Pathway	BIOCARTA_TGFB_PATHWAY	CREBBP EP300	6.65e-04	17	32	2	MM1509
Pathway	REACTOME_ZYGOTIC_GENOME_ACTIVATION_ZGA	CREBBP EP300	6.65e-04	17	32	2	M48025
Pathway	KEGG_MEDICUS_REFERENCE_DISASSEMBLY_OF_MCC	ANAPC1 CDC23	6.65e-04	17	32	2	M47888
Pathway	KEGG_HUNTINGTONS_DISEASE	CREBBP NDUFB10 EP300 SOD2	7.29e-04	182	32	4	M13486
Pathway	REACTOME_RORA_ACTIVATES_GENE_EXPRESSION	CREBBP EP300	7.47e-04	18	32	2	M26942
Pathway	BIOCARTA_TGFB_PATHWAY	CREBBP EP300	8.33e-04	19	32	2	M18933
Pathway	REACTOME_NFE2L2_REGULATING_ANTI_OXIDANT_DETOXIFICATION_ENZYMES	CREBBP EP300	8.33e-04	19	32	2	M46442
Pathway	REACTOME_CONVERSION_FROM_APC_C_CDC20_TO_APC_C_CDH1_IN_LATE_ANAPHASE	ANAPC1 CDC23	9.25e-04	20	32	2	MM14688
Pathway	REACTOME_PHOSPHORYLATION_OF_THE_APC_C	ANAPC1 CDC23	9.25e-04	20	32	2	MM14690
Pathway	REACTOME_CONVERSION_FROM_APC_C_CDC20_TO_APC_C_CDH1_IN_LATE_ANAPHASE	ANAPC1 CDC23	9.25e-04	20	32	2	M1044
Pathway	REACTOME_NOTCH4_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION	CREBBP EP300	9.25e-04	20	32	2	M27881
Pathway	REACTOME_PHOSPHORYLATION_OF_THE_APC_C	ANAPC1 CDC23	9.25e-04	20	32	2	M1050
Pathway	REACTOME_ABERRANT_REGULATION_OF_MITOTIC_EXIT_IN_CANCER_DUE_TO_RB1_DEFECTS	ANAPC1 CDC23	9.25e-04	20	32	2	M39015
Pathway	WP_CLEAR_CELL_RENAL_CELL_CARCINOMA_PATHWAYS	PTEN CREBBP EP300	9.57e-04	86	32	3	M39375
Pathway	REACTOME_INHIBITION_OF_THE_PROTEOLYTIC_ACTIVITY_OF_APC_C_REQUIRED_FOR_THE_ONSET_OF_ANAPHASE_BY_MITOTIC_SPINDLE_CHECKPOINT_COMPONENTS	ANAPC1 CDC23	1.02e-03	21	32	2	M489
Pathway	KEGG_MEDICUS_REFERENCE_SPINDLE_ASSEMBLY_CHECKPOINT_SIGNALING	ANAPC1 CDC23	1.02e-03	21	32	2	M47583
Pathway	REACTOME_CD209_DC_SIGN_SIGNALING	CREBBP EP300	1.02e-03	21	32	2	M27485
Pathway	REACTOME_INHIBITION_OF_THE_PROTEOLYTIC_ACTIVITY_OF_APC_C_REQUIRED_FOR_THE_ONSET_OF_ANAPHASE_BY_MITOTIC_SPINDLE_CHECKPOINT_COMPONENTS	ANAPC1 CDC23	1.02e-03	21	32	2	MM14560
Pathway	KEGG_PROSTATE_CANCER	PTEN CREBBP EP300	1.06e-03	89	32	3	M13191
Pathway	BIOCARTA_VDR_PATHWAY	CREBBP EP300	1.12e-03	22	32	2	MM1370
Pathway	BIOCARTA_NTHI_PATHWAY	CREBBP EP300	1.12e-03	22	32	2	MM1443
Pathway	WP_ANDROGEN_RECEPTOR_SIGNALING	PTEN CREBBP EP300	1.13e-03	91	32	3	M39700
Pathway	BIOCARTA_NTHI_PATHWAY	CREBBP EP300	1.23e-03	23	32	2	M2821
Pathway	REACTOME_CELLULAR_RESPONSE_TO_CHEMICAL_STRESS	ALB CREBBP EP300 SOD2	1.24e-03	210	32	4	M41836
Pathway	BIOCARTA_VDR_PATHWAY	CREBBP EP300	1.34e-03	24	32	2	M13404
Pathway	REACTOME_APC_C_CDC20_MEDIATED_DEGRADATION_OF_CYCLIN_B	ANAPC1 CDC23	1.34e-03	24	32	2	MM14675
Pathway	REACTOME_APC_C_CDC20_MEDIATED_DEGRADATION_OF_CYCLIN_B	ANAPC1 CDC23	1.34e-03	24	32	2	M1039
Pathway	REACTOME_GLYCOGEN_METABOLISM	PYGB PYGM	1.45e-03	25	32	2	M27857
Pathway	REACTOME_NOTCH3_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION	CREBBP EP300	1.45e-03	25	32	2	M27880
Pathway	BIOCARTA_CARM_ER_PATHWAY	CREBBP EP300	1.57e-03	26	32	2	M2499
Pathway	REACTOME_APC_CDC20_MEDIATED_DEGRADATION_OF_NEK2A	ANAPC1 CDC23	1.57e-03	26	32	2	MM14697
Pathway	PID_HDAC_CLASSIII_PATHWAY	CREBBP EP300	1.57e-03	26	32	2	M32
Pathway	REACTOME_APC_CDC20_MEDIATED_DEGRADATION_OF_NEK2A	ANAPC1 CDC23	1.57e-03	26	32	2	M1079
Pathway	REACTOME_ATTENUATION_PHASE	CREBBP EP300	1.82e-03	28	32	2	M27254
Pathway	PID_RETINOIC_ACID_PATHWAY	CREBBP EP300	2.09e-03	30	32	2	M207
Pathway	KEGG_O_GLYCAN_BIOSYNTHESIS	GALNT14 GALNT10	2.09e-03	30	32	2	M6929
Pathway	REACTOME_TRAF6_MEDIATED_IRF7_ACTIVATION	CREBBP EP300	2.09e-03	30	32	2	M936
Pathway	WP_INITIATION_OF_TRANSCRIPTION_AND_TRANSLATION_ELONGATION_AT_THE_HIV1_LTR	CREBBP EP300	2.37e-03	32	32	2	M39521
Pathway	WP_CELL_CYCLE	ANAPC1 EP300 CDC23	2.49e-03	120	32	3	M39650
Pathway	WP_TYPE_2_PAPILLARY_RENAL_CELL_CARCINOMA	CREBBP EP300	2.68e-03	34	32	2	M39771
Pathway	WP_GLYCOGEN_METABOLISM	PYGB PYGM	2.68e-03	34	32	2	MM15985
Pathway	PID_HIF2PATHWAY	CREBBP EP300	2.68e-03	34	32	2	M44
Pathway	REACTOME_EVASION_BY_RSV_OF_HOST_INTERFERON_RESPONSES	CREBBP EP300	2.83e-03	35	32	2	M48246
Pathway	REACTOME_REGULATION_OF_APC_C_ACTIVATORS_BETWEEN_G1_S_AND_EARLY_ANAPHASE	ANAPC1 CDC23	2.83e-03	35	32	2	MM14689
Pathway	REACTOME_GASTRULATION	FOXA2 CREBBP EP300	3.06e-03	129	32	3	M46433
Pathway	PID_FRA_PATHWAY	MGP EP300	3.16e-03	37	32	2	M65
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_BY_THE_AP_2_TFAP2_FAMILY_OF_TRANSCRIPTION_FACTORS	CREBBP EP300	3.33e-03	38	32	2	M27757
Pathway	REACTOME_HSF1_DEPENDENT_TRANSACTIVATION	CREBBP EP300	3.33e-03	38	32	2	M27255
Pathway	REACTOME_DISEASES_OF_MITOTIC_CELL_CYCLE	ANAPC1 CDC23	3.33e-03	38	32	2	M39005
Pathway	REACTOME_SENESCENCE_ASSOCIATED_SECRETORY_PHENOTYPE_SASP	ANAPC1 CDC23	3.51e-03	39	32	2	MM14900
Pathway	PID_P53_DOWNSTREAM_PATHWAY	PTEN CREBBP EP300	3.62e-03	137	32	3	M145
Pathway	WP_GLYCOGEN_SYNTHESIS_AND_DEGRADATION	PYGB PYGM	3.69e-03	40	32	2	M39595
Pathway	PID_FOXM1_PATHWAY	CREBBP EP300	3.69e-03	40	32	2	M176
Pathway	PID_IFNG_PATHWAY	CREBBP EP300	3.69e-03	40	32	2	M161
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_BY_VENTX	ANAPC1 CDC23	3.87e-03	41	32	2	M29748
Pathway	WP_MALE_INFERTILITY	CREBBP EP300 SOD2	4.25e-03	145	32	3	M39856
Pathway	REACTOME_SUMOYLATION_OF_TRANSCRIPTION_COFACTORS	CREBBP EP300	4.45e-03	44	32	2	M27295
Pathway	PID_HNF3B_PATHWAY	ALB FOXA2	4.65e-03	45	32	2	M106
Pathway	KEGG_NOTCH_SIGNALING_PATHWAY	CREBBP EP300	5.06e-03	47	32	2	M7946
Pubmed	The SWI/SNF chromatin remodeling factor DPF3 regulates metastasis of ccRCC by modulating TGF-β signaling.	PYGB PYGM ALB EP300	7.25e-07	55	44	4	35945219
Pubmed	Cohesin regulates tissue-specific expression by stabilizing highly occupied cis-regulatory modules.	FOXA2 CREBBP EP300	1.05e-06	16	44	3	22780989
Pubmed	Loss of p300 accelerates MDS-associated leukemogenesis.	CREBBP EP300	1.56e-06	2	44	2	27881875
Pubmed	Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia.	CREBBP EP300	1.56e-06	2	44	2	34845315
Pubmed	p300 plays a critical role in maintaining cardiac mitochondrial function and cell survival in postnatal hearts.	CREBBP EP300	1.56e-06	2	44	2	19729597
Pubmed	CREB-binding protein/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer.	CREBBP EP300	1.56e-06	2	44	2	39287984
Pubmed	Exon deletions of the EP300 and CREBBP genes in two children with Rubinstein-Taybi syndrome detected by aCGH.	CREBBP EP300	1.56e-06	2	44	2	20717166
Pubmed	The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia.	CREBBP EP300	1.56e-06	2	44	2	25893291
Pubmed	Human T-lymphotropic virus type 1 p30(II) regulates gene transcription by binding CREB binding protein/p300.	CREBBP EP300	1.56e-06	2	44	2	11559821
Pubmed	CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.	CREBBP EP300	1.56e-06	2	44	2	32576962
Pubmed	Syndromic features and mild cognitive impairment in mice with genetic reduction on p300 activity: Differential contribution of p300 and CBP to Rubinstein-Taybi syndrome etiology.	CREBBP EP300	1.56e-06	2	44	2	19822209
Pubmed	A specific CBP/p300-dependent gene expression programme drives the metabolic remodelling in late stages of spermatogenesis.	CREBBP EP300	1.56e-06	2	44	2	24522976
Pubmed	CBP is required for environmental enrichment-induced neurogenesis and cognitive enhancement.	CREBBP EP300	1.56e-06	2	44	2	21847097
Pubmed	p300 or CBP is required for insulin-stimulated glucose uptake in skeletal muscle and adipocytes.	CREBBP EP300	1.56e-06	2	44	2	34813504
Pubmed	Rubinstein-Taybi Syndrome	CREBBP EP300	1.56e-06	2	44	2	20301699
Pubmed	GMF is an evolutionarily developed Adf/cofilin-super family protein involved in the Arp2/3 complex-mediated organization of the actin cytoskeleton.	GMFB GMFG	1.56e-06	2	44	2	20517925
Pubmed	Potential biomarker of metformin action.	CREBBP EP300	1.56e-06	2	44	2	24639469
Pubmed	The histone acetyl transferases CBP and p300 regulate stress response pathways in synovial fibroblasts at transcriptional and functional levels.	CREBBP EP300	1.56e-06	2	44	2	37816914
Pubmed	Binding of p300/CBP co-activators by polyoma large T antigen.	CREBBP EP300	1.56e-06	2	44	2	11438528
Pubmed	Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivators.	CREBBP EP300	1.56e-06	2	44	2	10918613
Pubmed	Histone Acetyltransferases p300 and CBP Coordinate Distinct Chromatin Remodeling Programs in Vascular Smooth Muscle Plasticity.	CREBBP EP300	1.56e-06	2	44	2	35502657
Pubmed	p300 and cAMP response element-binding protein-binding protein in skeletal muscle homeostasis, contractile function, and survival.	CREBBP EP300	1.56e-06	2	44	2	31898871
Pubmed	Germline or inducible knockout of p300 or CBP in skeletal muscle does not alter insulin sensitivity.	CREBBP EP300	1.56e-06	2	44	2	30888860
Pubmed	Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer.	CREBBP EP300	1.56e-06	2	44	2	27881443
Pubmed	Spatiotemporal expression of histone acetyltransferases, p300 and CBP, in developing embryonic hearts.	CREBBP EP300	1.56e-06	2	44	2	19272189
Pubmed	Differential contribution of p300 and CBP to regulatory element acetylation in mESCs.	CREBBP EP300	1.56e-06	2	44	2	32690000
Pubmed	CBP/p300 antagonises EGFR-Ras-Erk signalling and suppresses increased Ras-Erk signalling-induced tumour formation in mice.	CREBBP EP300	1.56e-06	2	44	2	30953353
Pubmed	Disrupting the CH1 domain structure in the acetyltransferases CBP and p300 results in lean mice with increased metabolic control.	CREBBP EP300	1.56e-06	2	44	2	21803292
Pubmed	HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter.	CREBBP EP300	1.56e-06	2	44	2	9811832
Pubmed	Two independent regions of simian virus 40 T antigen increase CBP/p300 levels, alter patterns of cellular histone acetylation, and immortalize primary cells.	CREBBP EP300	1.56e-06	2	44	2	24089570
Pubmed	Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease.	CREBBP EP300	1.56e-06	2	44	2	15706485
Pubmed	Isolation of novel human cDNA (hGMF-gamma) homologous to Glia Maturation Factor-beta gene.	GMFB GMFG	1.56e-06	2	44	2	9545571
Pubmed	AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.	CREBBP EP300	1.56e-06	2	44	2	39266679
Pubmed	A boy with classical Rubinstein-Taybi syndrome but no detectable mutation in the CREBBP and EP300 genes.	CREBBP EP300	1.56e-06	2	44	2	22303793
Pubmed	FOXA2 suppresses endometrial carcinogenesis and epithelial-mesenchymal transition by regulating enhancer activity.	PTEN FOXA2	1.56e-06	2	44	2	35703180
Pubmed	Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function.	CREBBP EP300	1.56e-06	2	44	2	34732714
Pubmed	Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition.	CREBBP EP300	1.56e-06	2	44	2	34019788
Pubmed	Endogenous CCAAT/enhancer binding protein beta and p300 are both regulated by growth hormone to mediate transcriptional activation.	CREBBP EP300	1.56e-06	2	44	2	15860545
Pubmed	Further delineation of an entity caused by CREBBP and EP300 mutations but not resembling Rubinstein-Taybi syndrome.	CREBBP EP300	1.56e-06	2	44	2	29460469
Pubmed	Expression of p300 and CBP is associated with poor prognosis in small cell lung cancer.	CREBBP EP300	1.56e-06	2	44	2	24551300
Pubmed	Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma.	CREBBP EP300	1.56e-06	2	44	2	33911074
Pubmed	The adenovirus 12 E1A proteins can bind directly to proteins of the p300 transcription co-activator family, including the CREB-binding protein CBP and p300.	CREBBP EP300	1.56e-06	2	44	2	9018065
Pubmed	Coactivators p300 and CBP maintain the identity of mouse embryonic stem cells by mediating long-range chromatin structure.	CREBBP EP300	1.56e-06	2	44	2	24648406
Pubmed	CBP and P300 regulate distinct gene networks required for human primary myoblast differentiation and muscle integrity.	CREBBP EP300	1.56e-06	2	44	2	30135524
Pubmed	Distribution of co-activators CBP and p300 during mouse oocyte and embryo development.	CREBBP EP300	1.56e-06	2	44	2	16596650
Pubmed	The p300 and CBP Transcriptional Coactivators Are Required for β-Cell and α-Cell Proliferation.	CREBBP EP300	1.56e-06	2	44	2	29217654
Pubmed	Differences in the interactions of oncogenic adenovirus 12 early region 1A and nononcogenic adenovirus 2 early region 1A with the cellular coactivators p300 and CBP.	CREBBP EP300	1.56e-06	2	44	2	10049825
Pubmed	CBP/p300 acetyltransferase activity in hematologic malignancies.	CREBBP EP300	1.56e-06	2	44	2	27380996
Pubmed	CREBBP and p300 lysine acetyl transferases in the DNA damage response.	CREBBP EP300	1.56e-06	2	44	2	29170789
Pubmed	Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis.	CREBBP EP300	1.56e-06	2	44	2	21555743
Pubmed	CBP/p300 induction is required for retinoic acid sensitivity in human mammary cells.	CREBBP EP300	1.56e-06	2	44	2	12646247
Pubmed	Histone acetyltransferase activities of cAMP-regulated enhancer-binding protein and p300 in tissues of fetal, young, and old mice.	CREBBP EP300	1.56e-06	2	44	2	11867645
Pubmed	Expression of the nuclear coactivators CBP and p300 in developing craniofacial tissue.	CREBBP EP300	1.56e-06	2	44	2	11963968
Pubmed	Differential transcriptional activation by human T-cell leukemia virus type 1 Tax mutants is mediated by distinct interactions with CREB binding protein and p300.	CREBBP EP300	1.56e-06	2	44	2	9528808
Pubmed	Analysis of genetic stability at the EP300 and CREBBP loci in a panel of cancer cell lines.	CREBBP EP300	1.56e-06	2	44	2	12696060
Pubmed	CBP Is Required for Establishing Adaptive Gene Programs in the Adult Mouse Brain.	CREBBP EP300	1.56e-06	2	44	2	36109165
Pubmed	Retinoids and retinoic acid receptors regulate growth arrest and apoptosis in human mammary epithelial cells and modulate expression of CBP/p300.	CREBBP EP300	1.56e-06	2	44	2	12242694
Pubmed	CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms.	CREBBP EP300	1.56e-06	2	44	2	31182547
Pubmed	Rubinstein-Taybi syndrome in a Saudi boy with distinct features and variants in both the CREBBP and EP300 genes: a case report.	CREBBP EP300	1.56e-06	2	44	2	30635043
Pubmed	CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy.	PTEN CREBBP	1.56e-06	2	44	2	24491799
Pubmed	Phenotype and genotype in 52 patients with Rubinstein-Taybi syndrome caused by EP300 mutations.	CREBBP EP300	1.56e-06	2	44	2	27648933
Pubmed	Developmentally regulated expression of the transcriptional cofactors/histone acetyltransferases CBP and p300 during mouse embryogenesis.	CREBBP EP300	1.56e-06	2	44	2	10610021
Pubmed	Emerging roles of p300/CBP in autophagy and autophagy-related human disorders.	CREBBP EP300	1.56e-06	2	44	2	37314181
Pubmed	Isoform-selective regulation of glycogen phosphorylase by energy deprivation and phosphorylation in astrocytes.	PYGB PYGM	1.56e-06	2	44	2	25130497
Pubmed	Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal.	CREBBP EP300	1.56e-06	2	44	2	12397173
Pubmed	CBP/p300 TAZ1 domain forms a structured scaffold for ligand binding.	CREBBP EP300	1.56e-06	2	44	2	15641773
Pubmed	Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein.	CREBBP EP300	1.56e-06	2	44	2	9733868
Pubmed	Rubinstein-Taybi syndrome in Chinese population with four novel mutations.	CREBBP EP300	1.56e-06	2	44	2	33063428
Pubmed	EP300/CBP is crucial for cAMP-PKA pathway to alleviate podocyte dedifferentiation via targeting Notch3 signaling.	CREBBP EP300	1.56e-06	2	44	2	34506759
Pubmed	Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms.	CREBBP EP300	1.56e-06	2	44	2	22177454
Pubmed	Identification and isolation of a full-length clone of mouse GMFB (Gmfb), a putative intracellular kinase regulator, differentially expressed in telencephalon.	GMFB GMFG	1.56e-06	2	44	2	11435704
Pubmed	Mitochondrial H2O2 regulates the angiogenic phenotype via PTEN oxidation.	PTEN SOD2	1.56e-06	2	44	2	15701646
Pubmed	Galnt11 regulates kidney function by glycosylating the endocytosis receptor megalin to modulate ligand binding.	GALNT14 GALNT10 ALB	3.75e-06	24	44	3	31740596
Pubmed	The human T-cell leukemia virus type 1 tax protein confers CBP/p300 recruitment and transcriptional activation properties to phosphorylated CREB.	CREBBP EP300	4.69e-06	3	44	2	18070920
Pubmed	Human indolethylamine N-methyltransferase: cDNA cloning and expression, gene cloning, and chromosomal localization.	NNMT INMT	4.69e-06	3	44	2	10552930
Pubmed	Alterations in Sod2-Induced Oxidative Stress Affect Endocrine Cancer Progression.	PTEN SOD2	4.69e-06	3	44	2	30165401
Pubmed	Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.	CREBBP EP300	4.69e-06	3	44	2	27903646
Pubmed	Inhibition of p300/CBP by early B-cell factor.	CREBBP EP300	4.69e-06	3	44	2	12748286
Pubmed	Genetic interaction between mutations in c-Myb and the KIX domains of CBP and p300 affects multiple blood cell lineages and influences both gene activation and repression.	CREBBP EP300	4.69e-06	3	44	2	24340053
Pubmed	Acetylation of Nrf2 by p300/CBP augments promoter-specific DNA binding of Nrf2 during the antioxidant response.	CREBBP EP300	4.69e-06	3	44	2	19273602
Pubmed	Phorbol ester stimulates rapid intracellular phosphorylation of glia maturation factor.	GMFB GMFG	4.69e-06	3	44	2	7598724
Pubmed	Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation.	CREBBP EP300	4.69e-06	3	44	2	15649887
Pubmed	DUX4 recruits p300/CBP through its C-terminus and induces global H3K27 acetylation changes.	CREBBP EP300	4.69e-06	3	44	2	26951377
Pubmed	CBP/p300 and SIRT1 are involved in transcriptional regulation of S-phase specific histone genes.	CREBBP EP300	4.69e-06	3	44	2	21789216
Pubmed	Mastermind mediates chromatin-specific transcription and turnover of the Notch enhancer complex.	CREBBP EP300	4.69e-06	3	44	2	12050117
Pubmed	Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression.	CREBBP EP300	4.69e-06	3	44	2	16237459
Pubmed	The IFNgamma-induced STAT1-CBP/P300 association, required for a normal response to the cytokine, is disrupted in Brucella-infected macrophages.	CREBBP EP300	4.69e-06	3	44	2	19041714
Pubmed	Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP.	CREBBP EP300	4.69e-06	3	44	2	12776737
Pubmed	Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation.	CREBBP EP300	4.69e-06	3	44	2	14759370
Pubmed	Structures of KIX domain of CBP in complex with two FOXO3a transactivation domains reveal promiscuity and plasticity in coactivator recruitment.	CREBBP EP300	4.69e-06	3	44	2	22474372
Pubmed	Interferon regulatory factor 3 and CREB-binding protein/p300 are subunits of double-stranded RNA-activated transcription factor DRAF1.	CREBBP EP300	4.69e-06	3	44	2	9488451
Pubmed	Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression.	CREBBP EP300	4.69e-06	3	44	2	15782138
Pubmed	p300/CREB-binding protein interacts with ATR and is required for the DNA replication checkpoint.	CREBBP EP300	4.69e-06	3	44	2	17272271
Pubmed	Transcriptional activity of interferon regulatory factor (IRF)-3 depends on multiple protein-protein interactions.	CREBBP EP300	4.69e-06	3	44	2	12473110
Pubmed	Transcriptional coactivators CBP and p300 cooperatively enhance HNF-1alpha-mediated expression of the albumin gene in hepatocytes.	CREBBP EP300	4.69e-06	3	44	2	15598887
Pubmed	The acetate/ACSS2 switch regulates HIF-2 stress signaling in the tumor cell microenvironment.	CREBBP EP300	4.69e-06	3	44	2	25689462
Pubmed	Conditional knockout mice reveal distinct functions for the global transcriptional coactivators CBP and p300 in T-cell development.	CREBBP EP300	4.69e-06	3	44	2	16428436
Pubmed	Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators.	CREBBP EP300	4.69e-06	3	44	2	11823864
Pubmed	An essential role for p300/CBP in the cellular response to hypoxia.	CREBBP EP300	4.69e-06	3	44	2	8917528
Pubmed	In vitro enhancement of p38 mitogen-activated protein kinase activity by phosphorylated glia maturation factor.	GMFB GMFG	4.69e-06	3	44	2	8798479
Interaction	GMFG interactions	GMFB EP300 GMFG	8.56e-06	19	43	3	int:GMFG
Interaction	UBE2S interactions	PTEN ANAPC1 CREBBP EP300 CDC23	1.09e-05	138	43	5	int:UBE2S
Interaction	ANAPC5 interactions	PTEN ANAPC1 CREBBP EP300 CDC23	1.09e-05	138	43	5	int:ANAPC5
Interaction	ANAPC7 interactions	PTEN ANAPC1 CREBBP EP300 CDC23	2.37e-05	162	43	5	int:ANAPC7
Interaction	LATS1 interactions	TJP2 PYGM ALB MGP PTEN ANAPC1 CREBBP	3.68e-05	440	43	7	int:LATS1
Interaction	COX6B2 interactions	PTEN FRMD6	4.43e-05	5	43	2	int:COX6B2
Interaction	MAGIX interactions	TJP2 ANAPC1 CDC23	5.65e-05	35	43	3	int:MAGIX
Interaction	BBC3 interactions	ALB CREBBP EP300	7.25e-05	38	43	3	int:BBC3
Interaction	CCN2 interactions	PTEN CREBBP EP300	8.46e-05	40	43	3	int:CCN2
Cytoband	7p14.3	ZPBP INMT	6.17e-04	38	44	2	7p14.3
Cytoband	16p13.3	NAA60 CREBBP NDUFB10	1.67e-03	244	44	3	16p13.3
Cytoband	Ensembl 112 genes in cytogenetic band chr14q22	GMFB FRMD6	3.71e-03	94	44	2	chr14q22
GeneFamily	Glycogen phosphorylases	PYGB PYGM	7.98e-06	3	30	2	437
GeneFamily	Anaphase promoting complex \|Tetratricopeptide repeat domain containing	ANAPC1 CDC23	2.39e-04	14	30	2	402
GeneFamily	Zinc fingers ZZ-type\|Lysine acetyltransferases	CREBBP EP300	3.56e-04	17	30	2	486
GeneFamily	Zinc fingers ZZ-type\|Lysine acetyltransferases	CREBBP EP300	4.01e-04	18	30	2	91
GeneFamily	Polypeptide N-acetylgalactosaminyltransferases	GALNT14 GALNT10	4.96e-04	20	30	2	433
Coexpression	GSE17721_PAM3CSK4_VS_GADIQUIMOD_2H_BMDC_DN	GMFB IP6K1 SH2D1B ANAPC1 TM9SF3	2.10e-05	200	44	5	M3965
Coexpression	GSE17721_PAM3CSK4_VS_CPG_8H_BMDC_UP	IP6K1 FRMD6 ANAPC1 NDUFB10 TM9SF3	2.10e-05	200	44	5	M3865
CoexpressionAtlas	EB bone marrow_vs_EB blastocyst-Confounder_removed-fold2.0_adjp0.05	OGFRL1 C1R PYGM GALNT10 ALB MGP NNMT INMT	2.71e-06	446	43	8	PCBC_ratio_EB bone marrow_vs_EB blastocyst_cfr-2X-p05
ToppCell	distal-mesenchymal-Myofibroblast-1\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	IL1RAPL1 C1R MGP STEAP2 FRMD6 NNMT IBSP	9.94e-10	199	44	7	79917b5225cb45b4a0ea937f79f1752346e4346e
ToppCell	390C-Fibroblasts-Fibroblast-A_(Fibroblast_progenitors)\|390C / Donor, Lineage, Cell class and subclass (all cells)	C1R MGP STEAP2 NNMT INMT SOD2	2.59e-08	183	44	6	28e1fc6498aaf8f42c4d6d4fa54ffff4c546d0d1
ToppCell	390C-Fibroblasts-Fibroblast-A_(Fibroblast_progenitors)-\|390C / Donor, Lineage, Cell class and subclass (all cells)	C1R MGP STEAP2 NNMT INMT SOD2	2.59e-08	183	44	6	667d9107af17fd076ceff6b2cbcb78f892fd62d2
ToppCell	IPF-Stromal-Myofibroblast\|IPF / Disease state, Lineage and Cell class	C1R MGP STEAP2 FRMD6 NNMT INMT	3.89e-08	196	44	6	2d0a48e49b3b37bb66e33e74c52915911e1f8a74
ToppCell	IPF-Stromal-Myofibroblast\|World / Disease state, Lineage and Cell class	C1R MGP STEAP2 FRMD6 NNMT INMT	3.89e-08	196	44	6	7fc9894ceb79dab9f0495acc84e2d6d0d1c69bb7
ToppCell	IPF-Stromal\|IPF / Disease state, Lineage and Cell class	C1R MGP STEAP2 FRMD6 NNMT INMT	4.14e-08	198	44	6	ece914c32c9b123b779aa9624b92e6230763a20e
ToppCell	distal-1-mesenchymal-Myofibroblast\|1 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	IL1RAPL1 C1R MGP STEAP2 FRMD6 NNMT	4.26e-08	199	44	6	58c36f5a30c6862b7f5587a0b9bc31da99e43dd5
ToppCell	tumor_Lymph_Node_/_Brain-Fibroblasts-COL13A1+_matrix_FBs\|tumor_Lymph_Node_/_Brain / Location, Cell class and cell subclass	C1R MGP FRMD6 NNMT INMT	8.30e-07	176	44	5	510f9a14dc1c151d24d079e0cc004cdf4f86336c
ToppCell	5'-Adult-Distal_Rectal-Mesenchymal-fibroblastic-mLN_Stroma_(FMO2+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	C1R MGP STEAP2 NNMT SOD2	1.06e-06	185	44	5	9faa35ceb89ccd2979072286f063687c9f846ce3
ToppCell	Smart-start-Cell-Wel_seq-Neoplastic-Differentiated-like-MES-like-MES-like_hypoxia_independent-C\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	C1R PTPRU MGP NNMT SOD2	1.09e-06	186	44	5	c30fd15f6b4b6edfbdf18a019aaad7fed3cf91fe
ToppCell	10x5'v1-week_14-16-Mesenchymal_myocytic-stroma-muscle\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	ATP1B4 MGP FRMD6 NNMT IBSP	1.09e-06	186	44	5	b5c1afbe065746ed662527b2f052321f200ba0a8
ToppCell	10x_3'_v2v3-Neoplastic-Differentiated-like-AC-like-AC-like-C\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	C1R MRPL38 MGP NNMT SOD2	1.24e-06	191	44	5	219e38df321cd41e2d0861ca01ab0d71bbbd4d9b
ToppCell	3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.4.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	C1R MGP FOXA2 NNMT INMT	1.24e-06	191	44	5	f00d6824bd138b192a996e9f7de57b235bb24c18
ToppCell	3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Peribronchial_fibroblasts-Peribronchial_fibroblasts_L.2.1.3.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	C1R MGP STEAP2 NNMT INMT	1.27e-06	192	44	5	c5f8e766453f87847b740d6988c524b3d0ef3765
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_2_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	C1R MGP STEAP2 FRMD6 NNMT	1.31e-06	193	44	5	9ab47b360bee1d4f1092c2269e58acebe9584021
ToppCell	Control-Stromal-Myofibroblast\|World / Disease state, Lineage and Cell class	C1R MGP STEAP2 NNMT INMT	1.34e-06	194	44	5	3c2266772c5b56e8e02a461e5193e29588028ee9
ToppCell	3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Peribronchial_fibroblasts\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	C1R MGP STEAP2 NNMT INMT	1.38e-06	195	44	5	1236dc60288c7dd91868e86e9174a2dacd3b11b3
ToppCell	10x_3'_v2v3-Neoplastic-Differentiated-like-MES-like-MES-like_hypoxia_independent-C\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	C1R MGP NNMT INMT SOD2	1.38e-06	195	44	5	5cc2731664146fe54efc4cebe30088a933be98e1
ToppCell	IPF-Stromal-Fibroblast\|World / Disease state, Lineage and Cell class	C1R MGP STEAP2 NNMT INMT	1.38e-06	195	44	5	9c32756edb54f0c211185d9a98073fe01fd1526a
ToppCell	COPD-Stromal-Myofibroblast\|COPD / Disease state, Lineage and Cell class	C1R MGP STEAP2 NNMT INMT	1.41e-06	196	44	5	af206bb5bbb8b604a6212acd79878bcc3d326cec
ToppCell	3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	C1R MGP STEAP2 NNMT INMT	1.41e-06	196	44	5	cecf82cd5e0a3835d655f5e7478578674a63ce25
ToppCell	3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	C1R MGP STEAP2 NNMT INMT	1.41e-06	196	44	5	9737a5f006d37b549f281e1863aca558e1e4dc99
ToppCell	368C\|World / Donor, Lineage, Cell class and subclass (all cells)	C1R MGP STEAP2 NNMT SOD2	1.45e-06	197	44	5	f41211923938e5d7bfe6bf24f604ab386f17ef10
ToppCell	10x3'2.3-week_12-13-Mesenchymal_osteo-stroma\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	C1R MGP FRMD6 NNMT IBSP	1.45e-06	197	44	5	63b63c6b2f842adb87bc83222ff86796bd9b58f6
ToppCell	3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	C1R MGP STEAP2 NNMT INMT	1.45e-06	197	44	5	94a9603cbd3516fbcce871909693b88f20d41713
ToppCell	COPD-Stromal-Myofibroblast\|World / Disease state, Lineage and Cell class	C1R MGP STEAP2 NNMT INMT	1.45e-06	197	44	5	d51f484b4e01ac64233950d0b97fa88825ea1dbb
ToppCell	COPD-Stromal\|COPD / Disease state, Lineage and Cell class	C1R MGP STEAP2 NNMT INMT	1.45e-06	197	44	5	d5390d86acaa8c39f1da893e8d2271f9ed2951d7
ToppCell	COVID-19-Fibroblasts\|COVID-19 / group, cell type (main and fine annotations)	C1R MGP STEAP2 FRMD6 NNMT	1.45e-06	197	44	5	fb847f2277609c31fffcdf49517243ce0684facf
ToppCell	10x3'2.3-week_12-13-Mesenchymal_osteo\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	C1R MGP FRMD6 NNMT IBSP	1.45e-06	197	44	5	fb50903b87498b400c8e16e6a561b6d9458e5d97
ToppCell	3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_1-Subpleural_fibroblasts-Subpleural_fibroblasts_L.2.1.5.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	C1R STEAP2 NNMT INMT SOD2	1.48e-06	198	44	5	c66097ae9ba0b50561083c423565665958ef0bb8
ToppCell	tumor_Lung-Fibroblasts-COL14A1+_matrix_FBs\|tumor_Lung / Location, Cell class and cell subclass	C1R MGP STEAP2 FRMD6 NNMT	1.48e-06	198	44	5	74f2c7ef702b25a5b99e56121229e678ed992524
ToppCell	distal-mesenchymal-Alveolar_Fibroblast-1\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	C1R MGP STEAP2 NNMT INMT	1.48e-06	198	44	5	7f728ca6d5317890c6fcde3ce6c10c0970d49a05
ToppCell	COPD-Stromal-Fibroblast\|World / Disease state, Lineage and Cell class	C1R MGP STEAP2 NNMT INMT	1.48e-06	198	44	5	2f13c0b3372af53d1bd85f9546f315c878580a71
ToppCell	10x3'2.3-week_14-16-Mesenchymal_osteo-stroma-osteoblast_precursor\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	C1R MGP FRMD6 NNMT IBSP	1.48e-06	198	44	5	9d61483b0decac2fe90045b3474843360b2c49b3
ToppCell	COPD-Stromal-Fibroblast\|COPD / Disease state, Lineage and Cell class	C1R MGP STEAP2 NNMT INMT	1.48e-06	198	44	5	7904af61473cb20064f7a3a1e1bfe8d5913cf317
ToppCell	Control-Stromal\|Control / Disease state, Lineage and Cell class	C1R MGP STEAP2 NNMT INMT	1.48e-06	198	44	5	ae726b6b7f0a4107899be4d32ac256ffa0bd8d59
ToppCell	356C-Fibroblasts-Fibroblast-J_(Lipofibroblast)\|356C / Donor, Lineage, Cell class and subclass (all cells)	GALNT14 C1R STEAP2 NNMT INMT	1.52e-06	199	44	5	675f7c56b03a7918e2d9ca99440df6f27ad8e838
ToppCell	distal-mesenchymal-Alveolar_Fibroblast-2\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	C1R MGP STEAP2 NNMT INMT	1.52e-06	199	44	5	28c1722deef3b8347371c7359be7c64b95780de3
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Vascular-Mural_cell-Perivascular_fibroblast\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	MMP21 C1R MGP STEAP2 INMT	1.52e-06	199	44	5	dfc5c7a4a093baa7158dd8d4d29a870d9c469a3f
ToppCell	(5)_Fibroblast-A_(Fibroblast_progenitors)\|World / Lung cell shreds - cell class (v4) and cell subclass (v4)	C1R MGP STEAP2 NNMT INMT	1.52e-06	199	44	5	b783917fe0a9725a680aa430a42f02ce294900ef
ToppCell	ASK452-Mesenchymal-Fibroblast\|ASK452 / Donor, Lineage and Cell class of Lung cells from Dropseq	C1R MGP FRMD6 NNMT INMT	1.52e-06	199	44	5	4d0bf2a4bd97e5a3bfe4570a201cc21bb9c4c1f6
ToppCell	356C-Fibroblasts-Fibroblast-J_(Lipofibroblast)-\|356C / Donor, Lineage, Cell class and subclass (all cells)	GALNT14 C1R STEAP2 NNMT INMT	1.52e-06	199	44	5	97d74985018816754d11a55b9fb689690ecb1374
ToppCell	ASK452-Mesenchymal\|ASK452 / Donor, Lineage and Cell class of Lung cells from Dropseq	C1R MGP FRMD6 NNMT INMT	1.52e-06	199	44	5	93e85e3731a9ece9aee3eb82c5dfdad331ee62d6
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Vascular-Mural_cell-Perivascular_fibroblast-G\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	MMP21 C1R MGP STEAP2 INMT	1.52e-06	199	44	5	c1760581c34b81d1d92c67500a1c8944e9cc6dad
ToppCell	3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-Adventitial_fibroblasts_L.2.1.4.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	C1R MGP STEAP2 NNMT INMT	1.52e-06	199	44	5	66b4ff23b2e83fb7e6a37fdafdef315cfa33d327
ToppCell	Biopsy_Other_PF-Mesenchymal-Myofibroblasts\|Biopsy_Other_PF / Sample group, Lineage and Cell type	C1R MGP STEAP2 FRMD6 NNMT	1.56e-06	200	44	5	e504570fd7eec1524c401b1cfa9d10822d80d994
ToppCell	Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Fibroblasts-4\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	C1R MGP STEAP2 FRMD6 NNMT	1.56e-06	200	44	5	8256511b099c3eab8e33194f90c9ff354e7cfe8e
ToppCell	medial-mesenchymal-Alveolar_Fibroblast-2\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	C1R MGP STEAP2 NNMT INMT	1.56e-06	200	44	5	5c0716bf375c8158f7dc2c82bf5eaf37af594dd0
ToppCell	Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Fibroblasts-2,_SCARA5-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	C1R MGP STEAP2 FRMD6 NNMT	1.56e-06	200	44	5	0b2614b8513693dd508c9003699049efd9abac52
ToppCell	390C-Fibroblasts\|390C / Donor, Lineage, Cell class and subclass (all cells)	C1R MGP STEAP2 NNMT INMT	1.56e-06	200	44	5	3abe0f017fee6057ba73bd661a2bc8ec9e2bfe38
ToppCell	Parenchyma_Control_(B.)-Stromal-TX\|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type	C1R MGP STEAP2 NNMT INMT	1.56e-06	200	44	5	0a86656d48e4238d0e4d592d477d29f7ba7c2ec0
ToppCell	356C-Fibroblasts\|356C / Donor, Lineage, Cell class and subclass (all cells)	C1R MGP STEAP2 NNMT INMT	1.56e-06	200	44	5	9c95329f0b26ff378de803030d4c28517b3adc85
ToppCell	medial-mesenchymal-Alveolar_Fibroblast\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	C1R MGP STEAP2 NNMT INMT	1.56e-06	200	44	5	c22cbfecee00183dd4be678f116ab9fd9ad0a4dd
ToppCell	Lung_Parenchyma-Severe-Mesenchymal\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	C1R MGP STEAP2 FRMD6 NNMT	1.56e-06	200	44	5	6ce8e2cf689523993d909a27daec3d6a5824d13c
ToppCell	Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	C1R MGP STEAP2 FRMD6 NNMT	1.56e-06	200	44	5	907427e85cebe5a18c8a310e2ffa0e180ea3cb77
ToppCell	390C-Fibroblasts-Fibroblast-H-\|390C / Donor, Lineage, Cell class and subclass (all cells)	C1R MGP STEAP2 NNMT INMT	1.56e-06	200	44	5	ec7d6a08e34bcad5b3bbff56ebef96ae17e4cefd
ToppCell	Bronchial-10x5prime-Stromal\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	C1R MGP STEAP2 NNMT INMT	1.56e-06	200	44	5	5ea12e17f50fefbf5534e487af3392b2fa2d13ad
ToppCell	Lung_Parenchyma-Control-Mesenchymal-Mesenchymal\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	C1R MGP STEAP2 NNMT INMT	1.56e-06	200	44	5	3fa7d9ea67f9cc55478d085da53babd03dbe9bb1
ToppCell	Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Fibroblasts-1\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	C1R MGP STEAP2 FRMD6 NNMT	1.56e-06	200	44	5	c3d4ce70ab51d74c9fe2f5864e52a4a9d7570e10
ToppCell	Bronchial-10x5prime-Stromal-Fibroblastic-Fibro_alveolar\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	C1R MGP STEAP2 NNMT INMT	1.56e-06	200	44	5	cb31cfcfa8e6d6cc610c4c22e97bc009dd8a9e7c
ToppCell	Parenchyma_Control_(B.)-Stromal-TX-Fibroblasts-4\|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type	C1R MGP STEAP2 FRMD6 NNMT	1.56e-06	200	44	5	7642a14855589b0b3f68dbdc9e4d3fc7291854f7
ToppCell	3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.4.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	C1R MGP STEAP2 NNMT INMT	1.56e-06	200	44	5	0e1f9e1622e5a0fd814a1e100f79cbca2e0dbfbb
ToppCell	(5)_Fibroblasts\|World / Lung cell shreds - cell class (v4) and cell subclass (v4)	C1R MGP STEAP2 NNMT INMT	1.56e-06	200	44	5	22c839f27d3abdf86bfabdfa305f205dd899a9dc
ToppCell	10x5'v1-week_14-16-Mesenchymal_osteo-stroma-osteochondral_precursor\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	C1R MGP FRMD6 NNMT IBSP	1.56e-06	200	44	5	ad3fb8ef0be45032369d1325024787fbe1dfb8d6
ToppCell	Parenchymal-10x3prime_v2-Stromal-Fibroblastic\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	C1R MGP STEAP2 NNMT INMT	1.56e-06	200	44	5	fd92d8250c6ad1e8bb46b303ac37f8dcf80387d8
ToppCell	Parenchyma_COVID-19-Stromal-TX-Fibroblasts-1\|Parenchyma_COVID-19 / Sample group, Lineage and Cell type	C1R MGP STEAP2 FRMD6 NNMT	1.56e-06	200	44	5	25d3865aa2ced11a5ed40013e83b47d942fdf582
ToppCell	Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Fibroblasts-4-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	C1R MGP STEAP2 FRMD6 NNMT	1.56e-06	200	44	5	4dbe21cb63569f28c7017cda065ea5ee00d7254e
ToppCell	Parenchymal-10x3prime_v2-Stromal-Fibroblastic-Fibro_peribronchial\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	C1R MGP STEAP2 NNMT INMT	1.56e-06	200	44	5	efdf7066b7dd43e35dbc0d2719b75f250cf54af2
ToppCell	medial-2-mesenchymal-Alveolar_Fibroblast\|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	C1R MGP STEAP2 NNMT INMT	1.56e-06	200	44	5	cc6062dac07916c29091fc6bee2b864d29e6525b
ToppCell	Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Fibroblasts-1-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	C1R MGP STEAP2 FRMD6 NNMT	1.56e-06	200	44	5	137f8f9d255c66336d4f8b44b2e3f3de721f2bf0
ToppCell	Parenchyma_COVID-19-Stromal-TX-Fibroblasts-4\|Parenchyma_COVID-19 / Sample group, Lineage and Cell type	C1R MGP STEAP2 FRMD6 NNMT	1.56e-06	200	44	5	bde938e5a18844fb8cc1d1be5a086809f7e2b97d
ToppCell	Lung_Parenchyma-Control-Mesenchymal\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	C1R MGP STEAP2 NNMT INMT	1.56e-06	200	44	5	1e75d1302c22e1b1666c19c0c9259d5cc8be16d5
ToppCell	390C-Fibroblasts-Fibroblast-H\|390C / Donor, Lineage, Cell class and subclass (all cells)	C1R MGP STEAP2 NNMT INMT	1.56e-06	200	44	5	671e731977c58a0c44c36b56422085d93d999aad
ToppCell	Parenchyma_COVID-19-Stromal-TX\|Parenchyma_COVID-19 / Sample group, Lineage and Cell type	C1R MGP STEAP2 FRMD6 NNMT	1.56e-06	200	44	5	8472baa74c48b67c5f08223025885c833458290b
ToppCell	Parenchymal-NucSeq-Stromal-Fibroblastic-Fibro_adventitial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	C1R MGP STEAP2 FRMD6 NNMT	1.56e-06	200	44	5	74e74123ea7bf38d337a3a0248a6a51437c6ab42
ToppCell	tumor_Lymph_Node_/_Brain-Fibroblasts\|tumor_Lymph_Node_/_Brain / Location, Cell class and cell subclass	C1R MGP FRMD6 NNMT INMT	1.56e-06	200	44	5	4f7e26b27bd51c32420ed8c2f52d070aee542159
ToppCell	Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Fibroblasts-4-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	C1R MGP STEAP2 FRMD6 NNMT	1.56e-06	200	44	5	444c72334df421375ae6fc69b0adfd4950d49a43
ToppCell	Parenchyma_COVID-19-Stromal-TX-Fibroblasts-2,_SCARA5\|Parenchyma_COVID-19 / Sample group, Lineage and Cell type	C1R MGP STEAP2 FRMD6 NNMT	1.56e-06	200	44	5	c338a08c1605527ab9aaf62ea151a19e8469dc6d
ToppCell	3'-Parenchyma_lung-Mesenchymal-Fibroblastic\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	C1R MGP STEAP2 NNMT INMT	1.56e-06	200	44	5	2e4ab7fbd94d3d865ef6188d3b4916d2bf1b8d89
ToppCell	3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_1-Subpleural_fibroblasts\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	C1R MGP STEAP2 NNMT INMT	1.56e-06	200	44	5	d64895354218ebd0217011bae0967a6883bbd1cd
ToppCell	Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Fibroblasts-2,_SCARA5\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	C1R MGP STEAP2 FRMD6 NNMT	1.56e-06	200	44	5	8d2ceb2080c67b20f452eeca605aa27a58033c04
ToppCell	Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Fibroblasts-4\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	C1R MGP STEAP2 FRMD6 NNMT	1.56e-06	200	44	5	5826c17da67bdaba3a828792279004218d8260c8
ToppCell	Parenchymal-10x5prime-Stromal-Fibroblastic\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	C1R MGP STEAP2 NNMT INMT	1.56e-06	200	44	5	6e3d1ae0ef84d3075afa40129a41169996462672
ToppCell	Entopeduncular-Endothelial-MURAL-M1(Rgs5Acta2)-M1_2-MURAL_Mural.Rgs5Acta2.Kcnj8_(Mural.Rgs5Acta2.Kcnj8)-\|Entopeduncular / BrainAtlas - Mouse McCarroll V32	NNMT INMT MYO1H GMFG	5.63e-06	118	44	4	3cebd17f4688cd43fe1283dc60957e87d5536810
ToppCell	Entopeduncular-Endothelial-MURAL-M1(Rgs5Acta2)-M1_2-MURAL_Mural.Rgs5Acta2.Kcnj8_(Mural.Rgs5Acta2.Kcnj8)\|Entopeduncular / BrainAtlas - Mouse McCarroll V32	NNMT INMT MYO1H GMFG	5.63e-06	118	44	4	71f63efc641cd07c870f7695118fb244929c1536
ToppCell	Entopeduncular-Endothelial-MURAL-M1(Rgs5Acta2)-M1_2\|Entopeduncular / BrainAtlas - Mouse McCarroll V32	NNMT INMT MYO1H GMFG	5.63e-06	118	44	4	61b00b001edb1954a5fffaf4dfe71708124a45e5
ToppCell	368C-Fibroblasts-Fibroblast-A_(Fibroblast_progenitors)-\|368C / Donor, Lineage, Cell class and subclass (all cells)	C1R MGP STEAP2 NNMT	1.53e-05	152	44	4	3a1414ba6a4972698c3262a00b124428835c35cb
ToppCell	368C-Fibroblasts-Fibroblast-A_(Fibroblast_progenitors)\|368C / Donor, Lineage, Cell class and subclass (all cells)	C1R MGP STEAP2 NNMT	1.53e-05	152	44	4	ee7855d76a49d07a032677a4dc83aa6116d50518
ToppCell	367C-Fibroblasts-Fibroblast-G-\|367C / Donor, Lineage, Cell class and subclass (all cells)	C1R MGP NNMT INMT	2.27e-05	168	44	4	b8c65542a0701ae31f49d332d87a64578e24b4e3
ToppCell	367C-Fibroblasts-Fibroblast-G\|367C / Donor, Lineage, Cell class and subclass (all cells)	C1R MGP NNMT INMT	2.27e-05	168	44	4	8c95093b1ea45826f62893edd3c410fe53b563a4
ToppCell	11.5-Distal-Mesenchymal-Mesenchyme_SERPINF1-high\|Distal / Age, Tissue, Lineage and Cell class	C1R PYGM NAA60 MGP	2.54e-05	173	44	4	6989c9cebcd81eccceac7e5a86152676ee959386
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	C1R MGP FRMD6 INMT	2.72e-05	176	44	4	cc6f65a7d2c622841c9d1ab3755586039d4ccc4d
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Mesenchymal-glomerular_mesenchymal_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	C1R MGP FRMD6 INMT	2.72e-05	176	44	4	e9152defb4fd41267fb33c42c01fd0c683280783
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	C1R MGP FRMD6 INMT	2.72e-05	176	44	4	a4d269075aa0efc46fa251b379f334e50c69391d
ToppCell	343B-Fibroblasts-Fibroblast-A_(Fibroblast_progenitors)-\|343B / Donor, Lineage, Cell class and subclass (all cells)	C1R MGP FRMD6 INMT	2.72e-05	176	44	4	2e94bbe17c0bb65dc58b4ebc0cb829258bd7373b
ToppCell	343B-Fibroblasts-Fibroblast-A_(Fibroblast_progenitors)\|343B / Donor, Lineage, Cell class and subclass (all cells)	C1R MGP FRMD6 INMT	2.72e-05	176	44	4	f33ab41d121b59d871ad7d48ca021524a027d2ef
ToppCell	5'-Adult-SmallIntestine-Mesenchymal-fibroblastic-Stromal_3_(C7+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	IL1RAPL1 C1R MGP STEAP2	2.78e-05	177	44	4	bd602db857f37869ef76d14c05ef522c509f08ee
ToppCell	390C-Fibroblasts-Fibroblast-G\|390C / Donor, Lineage, Cell class and subclass (all cells)	C1R MGP STEAP2 INMT	2.97e-05	180	44	4	137fc14859c89e1ecd98bee388bb58c04b835847
ToppCell	facs-Spleen-nan-3m\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	IP6K1 ALB MGP INMT	2.97e-05	180	44	4	c0c3144011856d005aebd5cdc79f89fee32083a8
ToppCell	390C-Fibroblasts-Fibroblast-G-\|390C / Donor, Lineage, Cell class and subclass (all cells)	C1R MGP STEAP2 INMT	2.97e-05	180	44	4	cd6790de050151fedfa2c5ea6ad58b72665414b2
Computational	Genes upregulated in subsets of cells of a given type within various tumors	C1R MGP NNMT	2.86e-04	50	28	3	GAVISH_3CA_MALIGNANT_METAPROGRAM_12_EMT_1
Computational	Genes upregulated in subsets of cells of a given type within various tumors	MGP NNMT SOD2	2.86e-04	50	28	3	GAVISH_3CA_METAPROGRAM_ENDOTHELIAL_HEV_1
Drug	artemether	PYGB PYGM SOD2	7.50e-06	20	44	3	CID000068911
Drug	3,5-dimethylphenyl isocyanate	PYGB PYGM	1.09e-05	3	44	2	CID000521488
Drug	5-ethyl-4-hydroxy-2-methyl-3(2H)-furanone	PYGB PYGM	1.09e-05	3	44	2	CID000093111
Drug	adenosine-5'-chloromethylphosphonate	PYGB PYGM	1.09e-05	3	44	2	CID000191554
Drug	salicyl alcohol	ALB SOD2	1.09e-05	3	44	2	ctd:C010631
Drug	hydan	PYGB PYGM	1.09e-05	3	44	2	CID000008360
Drug	EHMF	PYGB PYGM	1.09e-05	3	44	2	CID000033931
Drug	5'-deoxy-5'-fluoro-5'-(methylthio)adenosine	PYGB PYGM	1.09e-05	3	44	2	CID000147839
Drug	pyridoxal 5'-methylenephosphonate	PYGB PYGM	1.09e-05	3	44	2	CID003082249
Drug	Plp 5'-mpa	PYGB PYGM	1.09e-05	3	44	2	CID003082151
Drug	glucose-1,2-cyclic phosphate	PYGB PYGM	1.09e-05	3	44	2	CID000191723
Drug	3'-FFdUrd	PYGB PYGM	1.09e-05	3	44	2	CID000072260
Drug	2',3',4',5,5'-pentachloro-2-biphenylol	PYGB PYGM	1.09e-05	3	44	2	CID000119518
Drug	AC1L8XK3	PYGB PYGM	1.09e-05	3	44	2	CID000409735
Drug	N-acetyl-N'-beta-D-glucopyranosyl urea	PYGB PYGM	1.09e-05	3	44	2	CID000446801
Drug	NSC758405	PYGB PYGM	1.09e-05	3	44	2	CID000003201
Drug	3,5-dinitrophenyl phosphate	PYGB PYGM	1.09e-05	3	44	2	CID000151920
Drug	riboflavin tetraacetate	PYGB PYGM	1.09e-05	3	44	2	CID000094186
Drug	pyridoxal phosphoglucose	PYGB PYGM	1.09e-05	3	44	2	CID000196007
Drug	2,5-dimethyl-3-furanone	PYGB PYGM	1.09e-05	3	44	2	CID000085730
Drug	3,5-dinitrophenol	PYGB PYGM	1.09e-05	3	44	2	CID000011459
Drug	galocitabine	PYGB PYGM	2.18e-05	4	44	2	CID000065950
Drug	2,5-anhydro-D-mannitol 1-phosphate	PYGB PYGM	2.18e-05	4	44	2	CID000189134
Drug	AC1LAMW2	PYGB PYGM	2.18e-05	4	44	2	CID000491364
Drug	FdUrd-C8	PYGB PYGM	2.18e-05	4	44	2	CID000094262
Drug	CuPu(Im)2	ALB SOD2	2.18e-05	4	44	2	CID005487316
Drug	Mem-CC	PYGB PYGM	2.18e-05	4	44	2	CID003081269
Drug	5-deoxyribose-1-phosphate	PYGB PYGM	2.18e-05	4	44	2	CID000135786
Drug	ingliforib	PYGB PYGM	2.18e-05	4	44	2	CID006451325
Drug	uric acid riboside	PYGB PYGM	2.18e-05	4	44	2	CID000164933
Drug	2,7-naphthyridine	NNMT INMT	2.18e-05	4	44	2	CID000136066
Drug	pseudo-dl-glucose	PYGB PYGM	2.18e-05	4	44	2	CID000125259
Drug	BCIp4A	PYGB PYGM	2.18e-05	4	44	2	CID000192417
Drug	pyridoxal diphosphate	PYGB PYGM	2.18e-05	4	44	2	CID000125696
Drug	3'-chloromethotrexate	PYGB PYGM	2.18e-05	4	44	2	CID000097703
Drug	1-o-phosphonohex-2-ulose	PYGB PYGM MGP	2.38e-05	29	44	3	CID000000481
Drug	AC-759	PYGB PYGM NRSN1 MGP	2.51e-05	88	44	4	CID000005396
Drug	heptulose-2-P	PYGB PYGM	3.64e-05	5	44	2	CID000124823
Drug	m-anisidine	PYGB PYGM	3.64e-05	5	44	2	CID000010824
Drug	6-FPLP	PYGB PYGM	3.64e-05	5	44	2	CID000146246
Drug	gluconohydroximo-1,5-lactone	PYGB PYGM	3.64e-05	5	44	2	CID009576855
Drug	2-hydroxypropylphosphonate	PYGB PYGM	3.64e-05	5	44	2	CID000441028
Drug	DHPBU	PYGB PYGM	3.64e-05	5	44	2	CID000125914
Drug	6-FDPL	PYGB PYGM	3.64e-05	5	44	2	CID000129578
Drug	5'-isobutylthioinosine	PYGB PYGM	3.64e-05	5	44	2	CID003080910
Drug	3'-O-methylpyridoxal 5'-phosphate	PYGB PYGM	3.64e-05	5	44	2	CID003082179
Drug	GlcMan	PYGB PYGM	3.64e-05	5	44	2	CID000152120
Drug	U66985	PYGB PYGM	3.64e-05	5	44	2	CID000127224
Drug	indirubin-5-sulphonate	PYGB PYGM	3.64e-05	5	44	2	CID005288641
Drug	3,4-dimethoxy-N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-N-phenylbenzenesulfonamide	CREBBP EP300	3.64e-05	5	44	2	ctd:C575894
Drug	AC1O3M08	PYGB PYGM	3.64e-05	5	44	2	CID006331955
Drug	AC1LCUXJ	PYGB PYGM	3.64e-05	5	44	2	CID000656425
Drug	6-amino-5-bromouracil	PYGB PYGM	3.64e-05	5	44	2	CID000080578
Drug	etafenone	PYGB PYGM	3.64e-05	5	44	2	CID000003275
Drug	ddEtUrd	PYGB PYGM	3.64e-05	5	44	2	CID000451452
Drug	5-trifluoromethyl-2'-deoxycytidine	PYGB PYGM	3.64e-05	5	44	2	CID000125618
Drug	calcium hydroxide	ZPBP IBSP SOD2	4.60e-05	36	44	3	CID000014777
Drug	Ethylmaleimide	PYGM ALB SOD2	4.60e-05	36	44	3	ctd:D005033
Drug	sodium nitrate	PYGB PYGM SOD2	5.00e-05	37	44	3	ctd:C031618
Drug	CV-araU	PYGB PYGM	5.45e-05	6	44	2	CID006441877
Drug	2-thiothymidine	PYGB PYGM	5.45e-05	6	44	2	CID003005944
Drug	Carbocyclic Bvdc	PYGB PYGM	5.45e-05	6	44	2	CID006438602
Drug	DNPP	PYGB PYGM	5.45e-05	6	44	2	CID000067056
Drug	5-chloro-indole-2-carboxylic acid	PYGB PYGM	5.45e-05	6	44	2	CID000082693
Drug	2,2-dimethyl-3-hydroxybutyric acid	PYGB PYGM	5.45e-05	6	44	2	CID000152984
Drug	EdUMP	PYGB PYGM	5.45e-05	6	44	2	CID003085112
Drug	5'-deoxy-5'-chloroformycin	PYGB PYGM	5.45e-05	6	44	2	CID000126430
Drug	NSC-97433	PYGB PYGM	5.45e-05	6	44	2	CID000001803
Drug	5-n-propylthioadenosine	PYGB PYGM	5.45e-05	6	44	2	CID000656428
Drug	AzddCyd	PYGB PYGM	5.45e-05	6	44	2	CID000451374
Drug	5-Ffdru	PYGB PYGM	5.45e-05	6	44	2	CID000065561
Drug	AR-L57	PYGB PYGM	5.45e-05	6	44	2	CID000156890
Drug	Carbocyclic Ivdu	PYGB PYGM	5.45e-05	6	44	2	CID006439191
Drug	Glucose	C1R GMFB PYGM GALNT10 ALB PTEN FOXA2 CREBBP EP300 SOD2 TM9SF3	6.05e-05	1420	44	11	ctd:D005947
Drug	1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine	CREBBP EP300 SOD2	6.82e-05	41	44	3	ctd:D019307
Drug	eye gene	PYGB GMFB PYGM EP300 SOD2 GMFG	7.30e-05	369	44	6	CID000004782
Drug	monoisoamyl-2,3-dimercaptosuccinate	ALB FOXA2 SOD2	7.33e-05	42	44	3	ctd:C091888
Drug	alpha-(fluoromethyl)dehydroornithine	PYGB PYGM	7.62e-05	7	44	2	CID006439607
Drug	6-fluoropyridoxal	PYGB PYGM	7.62e-05	7	44	2	CID003080803
Drug	2',3'-dideoxy-3'-fluorocytidine	PYGB PYGM	7.62e-05	7	44	2	CID000356019
Drug	heptenitol	PYGB PYGM	7.62e-05	7	44	2	CID000188267
Drug	AC1L3372	PYGB PYGM	7.62e-05	7	44	2	CID000108025
Drug	1 Gpt	PYGB PYGM	7.62e-05	7	44	2	CID000101247
Drug	formycins	PYGB PYGM	7.62e-05	7	44	2	CID000512867
Drug	Promonta	PYGB PYGM	7.62e-05	7	44	2	CID000108494
Drug	5'-methylthioinosine	PYGB PYGM	7.62e-05	7	44	2	CID000161214
Drug	hydantocidin	PYGB PYGM	7.62e-05	7	44	2	CID000125429
Drug	SB 203580	GMFB ALB PTEN CREBBP EP300 SOD2	9.62e-05	388	44	6	ctd:C093642
Drug	AC1NUVX5	PYGB PYGM	1.01e-04	8	44	2	CID005461894
Drug	6-methylpurine	PYGB PYGM	1.01e-04	8	44	2	CID005287547
Drug	amorphin	PYGB PYGM	1.01e-04	8	44	2	CID000122792
Drug	Etafenone [inn]	PYGB PYGM	1.01e-04	8	44	2	CID000066659
Drug	Phosphates	PYGM ALB IBSP	1.17e-04	49	44	3	ctd:D010710
Drug	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	ALB PTEN CREBBP EP300 IBSP SOD2	1.17e-04	402	44	6	ctd:C093973
Drug	inulin	PYGB PYGM ALB SOD2	1.26e-04	133	44	4	CID000024763
Drug	Cu-PuPy	ALB SOD2	1.30e-04	9	44	2	CID000160313
Drug	6-benzyl-2-thiouracil	PYGB PYGM	1.30e-04	9	44	2	CID000685814
Drug	5'-methylthiotubercidin	PYGB PYGM	1.30e-04	9	44	2	CID000188350
Drug	alpha-maltosyl fluoride	PYGB PYGM	1.30e-04	9	44	2	CID000194237
Drug	5-Iodoribose 1-phosphate	PYGB PYGM	1.30e-04	9	44	2	CID003035973
Disease	Menke-Hennekam syndrome	CREBBP EP300	1.98e-06	2	42	2	cv:C5681632
Disease	Rubinstein-Taybi syndrome (implicated_via_orthology)	CREBBP EP300	1.98e-06	2	42	2	DOID:1933 (implicated_via_orthology)
Disease	Rubinstein-Taybi syndrome	CREBBP EP300	1.98e-06	2	42	2	cv:C0035934
Disease	RUBINSTEIN-TAYBI SYNDROME 1	CREBBP EP300	1.98e-06	2	42	2	C4551859
Disease	RUBINSTEIN-TAYBI SYNDROME 1	CREBBP EP300	1.98e-06	2	42	2	180849
Disease	Rubinstein-Taybi syndrome due to CREBBP mutations	CREBBP EP300	1.98e-06	2	42	2	cv:C4551859
Disease	Rubinstein-Taybi syndrome (is_implicated_in)	CREBBP EP300	1.98e-06	2	42	2	DOID:1933 (is_implicated_in)
Disease	Rubinstein-Taybi Syndrome	CREBBP EP300	1.98e-06	2	42	2	C0035934
Disease	Adenocarcinoma of lung (disorder)	TRPM6 ALB CREBBP EP300 SOD2	1.09e-05	206	42	5	C0152013
Disease	Adenoid Cystic Carcinoma	PYGB PTEN CREBBP EP300	1.26e-05	100	42	4	C0010606
Disease	Bladder Neoplasm	NRSN1 CREBBP EP300 SOD2	4.72e-05	140	42	4	C0005695
Disease	Malignant neoplasm of urinary bladder	NRSN1 CREBBP EP300 SOD2	4.86e-05	141	42	4	C0005684
Disease	Small cell carcinoma of lung	PTEN CREBBP EP300	6.32e-05	54	42	3	C0149925
Disease	Diffuse Large B-Cell Lymphoma	CREBBP EP300 SOD2	6.68e-05	55	42	3	C0079744
Disease	Uveitis	ALB SOD2	7.08e-05	9	42	2	C0042164
Disease	Dermatologic disorders	MMP21 PTEN SOD2	1.69e-04	75	42	3	C0037274
Disease	Pancreatic carcinoma	EP300 SOD2	3.33e-04	19	42	2	C0235974
Disease	Squamous cell carcinoma of esophagus	CREBBP EP300 SOD2	3.39e-04	95	42	3	C0279626
Disease	Pancreatic Neoplasm	PTEN EP300 SOD2	3.94e-04	100	42	3	C0030297
Disease	Malignant neoplasm of pancreas	PTEN EP300 SOD2	4.17e-04	102	42	3	C0346647
Disease	Nasopharyngeal carcinoma	PTEN SOD2	4.49e-04	22	42	2	C2931822
Disease	congenital diaphragmatic hernia (biomarker_via_orthology)	EP300 SOD2	5.35e-04	24	42	2	DOID:3827 (biomarker_via_orthology)
Disease	Nephrotic Syndrome	ALB SOD2	6.79e-04	27	42	2	C0027726
Disease	Sezary Syndrome	PTEN CREBBP	6.79e-04	27	42	2	C0036920
Disease	Squamous cell carcinoma	CREBBP EP300 SOD2	7.38e-04	124	42	3	C0007137
Disease	Drug-Induced Stevens Johnson Syndrome	ALB EP300	7.84e-04	29	42	2	C1274933
Disease	Toxic Epidermal Necrolysis	ALB EP300	7.84e-04	29	42	2	C0014518
Disease	Mycoplasma-Induced Stevens-Johnson Syndrome	ALB EP300	7.84e-04	29	42	2	C3658301
Disease	Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum	ALB EP300	7.84e-04	29	42	2	C3658302
Disease	renal cell carcinoma (is_marker_for)	MGP PTEN NNMT	8.09e-04	128	42	3	DOID:4450 (is_marker_for)
Disease	Myopathy	PYGM ALB	8.39e-04	30	42	2	C0026848
Disease	Stevens-Johnson Syndrome	ALB EP300	8.39e-04	30	42	2	C0038325
Disease	Malignant neoplasm of brain	PTEN SOD2	1.35e-03	38	42	2	C0153633
Disease	Brain Neoplasms	PTEN SOD2	1.42e-03	39	42	2	C0006118

Protein segments in the cluster

Peptide	Gene	Start	Entry
PRDATYYSYQNRYHF	EP300	1186	Q09472
FYCLYYYRRAHQLRP	CDC23	416	Q9UJX2
KYLYEIARRHPYFYA	ALB	161	P02768
IPRDAAYYSYQNRYH	CREBBP	1221	Q92793
NTYKARIQYYCHEPY	C1R	396	P00736
FDLRYYPYYGKLTHV	ATP1B4	291	Q9UN42
PYVDHYYRDYPTLVR	ANAPC1	801	Q9H1A4
ARDLYKYRHQYPNFK	OGFRL1	96	Q5TC84
YSYKYVHDDGRVSYP	GMFG	71	O60234
YQKHFLPRDYLATYY	INMT	11	O95050
ENRDFKQHHYLPYYY	NAA60	151	Q9H7X0
KQHHYLPYYYSIRGV	NAA60	156	Q9H7X0
YAEYIYQRRPEYRHL	GALNT10	401	Q86SR1
YYVFPYLRNHSAYNA	DOP1B	1931	Q9Y3R5
QKHYYRSYEYDVPPT	IL1RAPL1	621	Q9NZN1
HPFRNIDSAYYSYAY	MMP21	501	Q8N119
YLSHFNPRDYLEKYY	NNMT	11	P40261
IERQHAKNRYYYYHR	NDUFB10	46	O96000
YQRYGVRSYLHQFYE	NRSN1	21	Q8IZ57
YYHHPQDRDRYYRNY	HNRNPUL2	726	Q1KMD3
RKGRDHYAYSYYPKP	PTPRU	771	Q92729
YKQYYYAARPFALER	GALNT14	366	Q96FL9
YSHYYHYYSRRLAPK	DNAJC25	131	Q9H1X3
RAARYYYYWHLRKQV	FRMD6	126	Q96NE9
HLVDRYNLYYAYLPA	TMEM63B	656	Q5T3F8
HPDTSYYIRYRGAVY	FEM1A	386	Q9BSK4
YQLDTGHYLCRNKYY	IP6K1	266	Q92551
QSYLVRNYHYSSYRP	KRTAP24-1	201	Q3LI83
YGYNAAYNRYFRKRR	MGP	86	P08493
YYYSYLLKNHLDYRP	PTEN	176	P60484
YRRSYTHAKPPYSYI	FOXA2	151	Q9Y261
YSYKYQHDDGRVSYP	GMFB	71	P60983
PRYYLYKHAYFYPHL	IBSP	41	P21815
LAAAYQLYYGTKYRR	STEAP2	276	Q8NFT2
YTYRIFREKHGYYRI	SH2D1B	51	O14796
YYARHYLYTRNKPAD	CNNM4	596	Q6P4Q7
RAYHRAYDPDYERAY	TJP2	251	Q9UDY2
YNRYRYIMTYHEKPW	TRPM6	1086	Q9BX84
YHKQRLAEYYGLYRD	MRPL38	146	Q96DV4
TQQHYYEKDPKRIYY	PYGM	71	P11217
TQQHYYERDPKRIYY	PYGB	71	P11216
EHAYYLQYKNVRPDY	SOD2	186	P04179
QLKYAIYAYREPHYY	ZPBP	156	Q9BS86
YHNRQETYKYFSLPF	TM9SF3	51	Q9HD45
GFAYRRKYEHFLQRY	MYO1H	631	Q8N1T3